Literature DB >> 16393691

Cyclins: roles in mitogenic signaling and oncogenic transformation.

Elizabeth A Musgrove1.   

Abstract

Cyclins are the regulatory subunits of kinases that control progress through the cell cycle. This review focuses on cyclins that are targets for extracellular signaling and frequently deregulated during oncogenesis, particularly cyclin D1. Receptor tyrosine kinases and adhesion molecules act through various effector pathways to modulate cyclin D1 abundance at multiple levels including transcription, translation and protein stability. In contrast, cyclin E-Cdk2 activity appears to be more commonly regulated by means other than regulation of cyclin E abundance. The importance of these pathways during oncogenesis is illustrated by the dependence of oncogenes such as Ras and Neu/ErbB2 on cyclin D1. Thus, understanding the roles of cyclins in growth factor and adhesion signaling is important for understanding the biology of both normal and neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16393691     DOI: 10.1080/08977190500361812

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  57 in total

1.  Segment- and cell-specific expression of D-type cyclins in the postnatal mouse epididymis.

Authors:  Huizhen Wang; T Rajendra Kumar
Journal:  Gene Expr Patterns       Date:  2012-01-24       Impact factor: 1.224

2.  The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells.

Authors:  Kelly J Morgan; Matthew A Rowley; Stephen M Wiesner; Diane E Hasz; Brian Van Ness; David A Largaespada
Journal:  Leuk Res       Date:  2007-01-12       Impact factor: 3.156

3.  Actinomycin D inhibits cell proliferations and promotes apoptosis in osteosarcoma cells.

Authors:  Dai-Feng Lu; Yan-Song Wang; Chao Li; Guo-Jun Wei; Rui Chen; Da-Ming Dong; Meng Yao
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 4.  Anaplastic thyroid cancer, tumorigenesis and therapy.

Authors:  J P O'Neill; D Power; C Condron; D Bouchier-Hayes; M Walsh
Journal:  Ir J Med Sci       Date:  2009-08-07       Impact factor: 1.568

Review 5.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

Review 6.  CDK4 inhibitors an emerging strategy for the treatment of melanoma.

Authors:  Belinda Lee; Grant A McArthur
Journal:  Melanoma Manag       Date:  2015-08-10

7.  Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis.

Authors:  Bumsup Kwon; Pravir Kumar; Han-Kyu Lee; Ling Zeng; Kenneth Walsh; Qinghao Fu; Amey Barakat; Henry W Querfurth
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

8.  Differential roles of cyclin D1 and D3 in pancreatic ductal adenocarcinoma.

Authors:  Nikolina Radulovich; Nhu-An Pham; Dan Strumpf; Lisa Leung; Wing Xie; Igor Jurisica; Ming-Sound Tsao
Journal:  Mol Cancer       Date:  2010-02-01       Impact factor: 27.401

9.  Regulation of C/EBPbeta1 by Ras in mammary epithelial cells and the role of C/EBPbeta1 in oncogene-induced senescence.

Authors:  A A Atwood; L Sealy
Journal:  Oncogene       Date:  2010-09-06       Impact factor: 9.867

10.  Overexpression of Spry1 in chondrocytes causes attenuated FGFR ubiquitination and sustained ERK activation resulting in chondrodysplasia.

Authors:  Xuehui Yang; Lauren K Harkins; Olga Zubanova; Anne Harrington; Dmitry Kovalenko; Robert J Nadeau; Pei-Yu Chen; Jessica L Toher; Volkhard Lindner; Lucy Liaw; Robert Friesel
Journal:  Dev Biol       Date:  2008-06-09       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.